Clinical Trial

Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi

Study acronym: FIL_GAZEBO
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Prospective, multicenter, open label, phase III randomized clinical trial in previously untreated Follicular Lymphoma in early stage. Patients will be randomized to receive Radiotherapy or Radiotherapy plus Obinutuzumab.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2023-06-26; most recent amendment 2026-05-29.
Status change: Not Yet Recruiting → Recruiting 2024-02-22
Trial Details
NCT Number NCT05929222
Lead Sponsor Fondazione Italiana Linfomi - ETS
Conditions Follicular Lymphoma
Enrollment 190 participants
Start Date 2023-12-14
Primary Completion 2031-04 (estimated)
Study Completion 2031-04 (estimated)
Updated on ClinicalTrials.gov 2026-06-01